Online inquiry

IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ14304MR)

This product GTTS-WQ14304MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets ANGPT2&VEGFA gene. The antibody can be applied in Solid tumors, Colorectal Cancer (CRC) Cancers (CRC) Cancer (CRC) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_001118887.2; NM_001025366.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 285; 7422
UniProt ID O15123; P15692
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-ANGPT2&VEGFA, RG-7221(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ14304MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2923MR IVTScrip™ mRNA-Anti-ERBB3, AMG888(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AMG888
GTTS-WQ11566MR IVTScrip™ mRNA-Anti-CD276, MG-A271(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MG-A271
GTTS-WQ4407MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ8930MR IVTScrip™ mRNA-Anti-IL1B, IL-1 Trap(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA IL-1 Trap
GTTS-WQ4390MR IVTScrip™ mRNA-Anti-B7, BMS-224818(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-224818
GTTS-WQ6045MR IVTScrip™ mRNA-Anti-IL6, CNTO 136(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CNTO 136
GTTS-WQ5117MR IVTScrip™ mRNA-Anti-CD52, Campath-1H(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Campath-1H
GTTS-WQ14746MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-19A
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW